Tocilizumab in refractory Caucasian Takayasu's arteritis: a multicenter study of 54 patients and literature review

被引：18

作者：

Prieto-Pena, Diana ^{[4
]}

Bernabeu, Pilar ^{[5
]}

Vela, Paloma ^{[5
]}

Narvaez, Javier ^{[6
]}

Fernandez-Lopez, Jesus C. ^{[7
]}

Freire-Gonzalez, Mercedes ^{[7
]}

Gonzalez-Alvarez, Beatriz ^{[8
]}

Solans-Laque, Roser ^{[9
]}

Callejas Rubio, Jose L. ^{[10
]}

Ortego, Norberto ^{[10
]}

Fernandez-Diaz, Carlos ^{[11
]}

Rubio, Esteban ^{[12
]}

Garcia-Morillo, Salvador ^{[12
]}

Minguez, Mauricio ^{[13
]}

Fernandez-Carballido, Cristina ^{[13
]}

de Miguel, Eugenio ^{[14
]}

Melchor, Sheila ^{[15
]}

Salgado, Eva ^{[16
]}

Bravo, Beatriz ^{[17
]}

Romero-Yuste, Susana ^{[18
]}

Salvatierra, Juan ^{[10
]}

Hidalgo, Cristina ^{[19
]}

Manrique, Sara ^{[20
]}

Romero-Gomez, Carlos ^{[20
]}

Moya, Patricia ^{[21
]}

Alvarez-Rivas, Noelia ^{[22
]}

Mendizabal, Javier ^{[23
]}

Ortiz-Sanjuan, Francisco ^{[24
]}

Perez de Pedro, Ivan ^{[25
]}

Alonso-Valdivielso, Jose L. ^{[26
]}

Perez-Sanchez, Laura ^{[27
]}

Roldan, Rosa ^{[27
]}

Fernandez-Llanio, Nagore ^{[28
]}

Gomez de la Torre, Ricardo ^{[29
]}

Suarez, Silvia ^{[29
]}

Montesa Cabrera, Maria Jesus ^{[8
]}

Delgado Sanchez, Monica ^{[8
]}

Loricera, Javier ^{[4
]}

Atienza-Mateo, Belen ^{[4
]}

Castaneda, Santos ^{[11
,30
]}

Gonzalez-Gay, Miguel A. ^{[1
,2
,3
]}

Blanco, Ricardo ^{[4
]}

机构：

[1] Hosp Univ Marques de Valdecilla, Rheumatol Div, Res Grp Genet Epidemiol & Atherosclerosis Syst Di, IDIVAL, Ave Valdecilla S-N, Santander 39008, Spain

[2] Univ Cantabria, Sch Med, Santander, Spain

[3] Univ Witwatersrand, Fac Hlth Sci, Sch Physiol, Cardiovasc Pathophysiol & Genom Res Unit, Johannesburg, South Africa

[4] Hosp Univ Marques de Valdecilla, Dept Rheumatol, IDIVAL, Res Grp Genet Epidemiol & Atherosclerosis Syst Di, Santander, Spain

[5] Hosp Gen Alicante, Dept Rheumatol, Alicante, Spain

[6] Hosp Bellvitge Princeps Espanya, Dept Rheumatol, Barcelona, Spain

[7] Complejo Hosp Univ A Coruna, Dept Rheumatol, La Coruna, Spain

[8] Hosp Nuestra Senora Candelaria, Dept Rheumatol, Tenerife, Spain

[9] Hosp Valle De Hebron, Dept Internal Med, Barcelona, Spain

[10] Hosp San Cecilio, Autoimmune Dis Unit, Granada, Spain

[11] Hosp Univ Princesa, Dept Rheumatol, IIS Princesa, Madrid, Spain

[12] Hosp Virgen Rocio, Autoimmune Dis Unit, Seville, Spain

[13] Hosp San Juan Alicante, Dept Rheumatol, Alicante, Spain

[14] Hosp Univ La Paz, Dept Rheumatol, Madrid, Spain

[15] Hosp Univ 12 Octubre, Dept Rheumatol, Madrid, Spain

[16] Complejo Hosp Univ Ourense, Dept Rheumatol, Orense, Spain

[17] Hosp Virgen Nieves, Dept Rheumatol, Granada, Spain

[18] Complejo Hosp Univ Pontevedra, Dept Rheumatol, Pontevedra, Spain

[19] Complejo Univ Salamanca, Dept Rheumatol, Salamanca, Spain

[20] Hosp Reg Malaga, Autoimmune Dis Unit, Malaga, Spain

[21] Hosp Santa Creu & Sant Pau, Dept Rheumatol, Barcelona, Spain

[22] Hosp Univ San Agustin, Dept Rheumatol, Aviles, Spain

[23] Complejo Hosp Navarra, Dept Rheumatol, Pamplona, Spain

[24] Hosp Univ & Politecn La Fe, Dept Rheumatol, Valencia, Spain

[25] Hosp Carlos Haya, Autoimmune Dis Unit, Malaga, Spain

[26] Hosp Univ Burgos, Dept Rheumatol, Burgos, Spain

[27] Hosp Univ Reina Sofia, Dept Rheumatol, Cordoba, Spain

[28] Hosp Arnau Vilanova, Dept Rheumatol, Valencia, Spain

[29] Hosp Univ Cent Asturias, Autoimmune Dis Unit, Oviedo, Spain

[30] Univ Autonoma Madrid IUAMI, UAM ROCHE, EPID Future, Madrid, Spain

来源：

THERAPEUTIC ADVANCES IN MUSCULOSKELETAL DISEASE | 2021年 / 13卷

关键词：

biological therapy; Caucasian; cDMARDs; Takayasu's arteritis; Tocilizumab; DISEASE-ACTIVITY; EPIDEMIOLOGY; EFFICACY; FEATURES; CRITERIA; OUTCOMES; SAFETY; JAPAN;

D O I：

10.1177/1759720X211020917

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Objective: To assess the efficacy and safety of tocilizumab (TCZ) in Caucasian patients with refractory Takayasu's arteritis (TAK) in clinical practice. Methods: A multicenter study of Caucasian patients with refractory TAK who received TCZ. The outcome variables were remission, glucocorticoid-sparing effect, improvement in imaging techniques, and adverse events. A comparative study between patients who received TCZ as monotherapy (TCZ(MONO)) and combined with conventional disease modifying anti-rheumatic drugs (cDMARDs) (TCZ(COMBO)) was performed. Results: The study comprised 54 patients (46 women/8 men) with a median [interquartile range (IQR)] age of 42.0 (32.5-50.5) years. TCZ was started after a median (IQR) of 12.0 (3.0-31.5) months since TAK diagnosis. Remission was achieved in 12/54 (22.2%), 19/49 (38.8%), 23/44 (52.3%), and 27/36 (75%) patients at 1, 3, 6, and 12 months, respectively. The prednisone dose was reduced from 30.0 mg/day (12.5-50.0) to 5.0 (0.0-5.6) mg/day at 12 months. An improvement in imaging findings was reported in 28 (73.7%) patients after a median (IQR) of 9.0 (6.0-14.0) months. Twenty-three (42.6%) patients were on TCZ(MONO) and 31 (57.4%) on TCZ(COMBO): MTX (n = 28), cyclosporine A (n = 2), azathioprine (n = 1). Patients on TCZ(COMBO) were younger [38.0 (27.0-46.0) versus 45.0 (38.0-57.0)] years; difference (diff) [95% confidence interval (CI) = -7.0 (-17.9, -0.56] with a trend to longer TAK duration [21.0 (6.0-38.0) versus 6.0 (1.0-23.0)] months; diff 95% CI = 15 (-8.9, 35.5), and higher c-reactive protein [2.4 (0.7-5.6) versus 1.3 (0.3-3.3)] mg/dl; diff 95% CI = 1.1 (-0.26, 2.99). Despite these differences, similar outcomes were observed in both groups (log rank p = 0.862). Relevant adverse events were reported in six (11.1%) patients, but only three developed severe events that required TCZ withdrawal. Conclusion: TCZ in monotherapy, or combined with cDMARDs, is effective and safe in patients with refractory TAK of Caucasian origin.

引用

页数：12

共 50 条

[1] Tocilizumab in patients with Takayasu arteritis: a retrospective study and literature review
Loricera, J.
Blanco, R.
Hernandez, J. L.
Castaneda, S.
Humbria, A.
Ortego, N.
Bravo, B.
Freire, M.
Melchor, S.
Minguez, M.
Salvatierra, J.
Gonzalez-Vela, C.
Calvo-Rio, V.
Santos-Gomez, M.
Pina, T.
Gonzalez-Gay, M. A.
CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2016, 34 (03) : S44 - S53
[2] Systematic review and meta-analysis of the current literature on tocilizumab in patients with refractory Takayasu arteritis
Kang, Limei
Liu, Yang
Luo, Zhongling
Zhou, Yueyuan
Chen, Bo
Yin, Geng
Xie, Qibing
FRONTIERS IN IMMUNOLOGY, 2023, 14
[3] Efficacy of tocilizumab for refractory Takayasu arteritis: a retrospective study and literature review
Li, Haiyan
Shuai, Zongwen
HEART AND VESSELS, 2022, 37 (05) : 884 - 894
[4] Tocilizumab in refractory Takayasu arteritis: A case series and updated literature review
Abisror, Noemie
Mekinian, Arsene
Lavigne, Christian
Vandenhende, Marie-Anne
Soussan, Michael
Fain, Olivier
AUTOIMMUNITY REVIEWS, 2013, 12 (12) : 1143 - 1149
[5] Effectiveness and safety of tocilizumab in patients with refractory or severe Takayasu's arteritis: A prospective cohort study in a Chinese population
Wu, Sifan
Kong, Xiufang
Cui, Xiaomeng
Chen, Huiyong
Ma, Lili
Dai, Xiaomin
Ji, Zongfei
Yan, Yan
Huang, Qingrong
Sun, Ying
Jiang, Lindi
JOINT BONE SPINE, 2021, 88 (05)
[6] Tocilizumab treatment in childhood Takayasu arteritis: Case series of four patients and systematic review of the literature
Batu, Ezgi Deniz
Sonmez, Hafize Emine
Hazirolan, Tuncay
Ozaltin, Fatih
Bilginer, Yelda
Ozen, Seza
SEMINARS IN ARTHRITIS AND RHEUMATISM, 2017, 46 (04) : 529 - 535
[7] The efficacy of tocilizumab for the treatment of Chinese Takayasu's arteritis
Zhou, J.
Chen, Z.
Li, J.
Yang, Y.
Zhao, J.
Chen, H.
Liu, M.
Sun, F.
Li, M.
Tian, X.
Zeng, X.
CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2017, 35 (01) : S171 - S175
[8] Efficacy of tocilizumab in Takayasu arteritis: Multicenter retrospective study of 46 patients
Mekinian, Arsene
Resche-Rigon, Mathieu
Comarmond, Cloe
Soriano, Alessandra
Constans, Joel
Alric, Laurent
Jego, Patrick
Busato, Florian
Cabon, Matthieu
Dhote, Robin
Estibaliz, Lazaro
Pault, Isabelle Kone
Landron, Cedric
Lavigne, Christian
Lioger, Bertrand
Michaud, Martin
Ruivard, Marc
Sacre, Karim
Gottenberg, Jacques Eric
Gaches, Francis
Goulenok, Tiphaine
Salvarani, Carlo
Cacoub, Patrice
Fain, Olivier
Saadoun, David
JOURNAL OF AUTOIMMUNITY, 2018, 91 : 55 - 60
[9] Tocilizumab for the Treatment of Patients With Refractory Takayasu Arteritis
Nakaoka, Yoshikazu
Higuchi, Kaori
Arita, Yoh
Otsuki, Michio
Yamamoto, Kaori
Hashimoto-Kataka, Takahiro
Yasui, Taku
Ikeoka, Kuniyasu
Ohtani, Tomohito
Sakata, Yasushi
Shima, Yoshihito
Kumanogoh, Atsushi
Yamauchi-Takihara, Keiko
Tanaka, Toshio
Kishimoto, Tadamitsu
Komuro, Issei
INTERNATIONAL HEART JOURNAL, 2013, 54 (06) : 405 - 411
[10] Overall survival and mortality risk factors in Takayasu's arteritis: A multicenter study of 318 patients
Mirouse, Adrien
Biard, Lucie
Comarmond, Cloe
Lambert, Marc
Mekinian, Arsene
Ferfar, Yasmina
Kahn, Jean-Emmanuel
Benhamou, Ygal
Chiche, Laurent
Koskas, Fabien
Cluzel, Philippe
Hachulla, Eric
Messas, Emmanuel
Cacoub, Patrice
Mirault, Tristan
Resche-Rigon, Matthieu
Saadoun, David
JOURNAL OF AUTOIMMUNITY, 2019, 96 : 35 - 39

← 1 2 3 4 5 →